JAZZ - ジャズ・ファ―マシュ―ティカルズ （Jazz Pharmaceuticals plc）JAZZのニュース
Where Jazz Pharmaceuticals Stands With Analysts 2022/08/04 21:13:06 Business Insider Markets
Within the last quarter, Jazz Pharmaceuticals (NASDAQ: JAZZ ) has observed the following analyst ratings:…
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2022 Results - Earnings Call Transcript 2022/08/03 22:53:02 Seeking Alpha
Jazz Pharmaceuticals plc (NASDAQ:NASDAQ:JAZZ) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Andrea Flynn - Vice President & Head-Investor Relations…
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance 2022/08/03 20:10:00 Finanz Nachrichten
DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and provided busine…
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance 2022/08/03 20:05:00 PR Newswire Media
DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and provided business updates. "We''ve had a highly productive second quarter across commercial, R&D and…
Jazz Pharmaceuticals Q2 2022 Earnings Preview (NASDAQ:JAZZ) 2022/08/02 21:35:38 Seeking Alpha
Jazz Pharmaceuticals (JAZZ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close.The consensus EPS Estimate is $4.19 (+7.4% Y/Y) and the…
New filing by JAZZ PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE 2022/07/06 20:45:10 The FEC
The JAZZ PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE successfully filed their F3XA JUNE MONTHLY with the coverage period of 05/01/2022 to 05/31/2022 and a confirmation ID of FEC-1607047 *********CommitteeId: C00721811 | FilingId: 1607047 | FormType: F3XA | CoverageFrom: 05/01/2022 | CoverageThrough: 05/31/2022 | ReportType: JUNE MONTHLY*********
What SVB Says On Axsome''s Strategy Review On Sunosi For Sleeping Disorder 2022/06/29 19:22:57 Benzinga
Axsome Therapeutics Inc (NASDAQ: AXSM ) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its … Full story available on Benzinga.com
IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave 2022/06/29 19:11:15 Investor''s Business Daily
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
Jazz Pharma''s Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity 2022/06/28 13:13:05 Benzinga
Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) announced topline results from the Phase 3 RELEASE MSS1 trial of nabiximols oromucosal spray on clinical measures of spasticity in multiple sclerosis. The trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21. Nabiximols oromucosal spray is a … Full story available on Benzinga.com
Jazz cannabis spray for multiple sclerosis fails phase 3 trial 2022/06/28 12:14:49 Seeking Alpha
Jazz Pharmaceuticals (JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple…
What SVB Says On Axsome''s Strategy Review On Sunosi For Sleeping Disorder 2022/06/29 19:22:57 Benzinga
Axsome Therapeutics Inc (NASDAQ: AXSM ) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its … Full story available on Benzinga.com
IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave 2022/06/29 19:11:15 Investor''s Business Daily
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
Jazz Pharma''s Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity 2022/06/28 13:13:05 Benzinga
Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) announced topline results from the Phase 3 RELEASE MSS1 trial of nabiximols oromucosal spray on clinical measures of spasticity in multiple sclerosis. The trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21. Nabiximols oromucosal spray is a … Full story available on Benzinga.com
Jazz cannabis spray for multiple sclerosis fails phase 3 trial 2022/06/28 12:14:49 Seeking Alpha
Jazz Pharmaceuticals (JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple…
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity 2022/06/28 11:33:00 Finanz Nachrichten
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) toda…